LLYEli Lilly and CompanyRunning, no new patients
A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer
Non Small Cell Lung Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 453 (final count)
- Started
- Oct 3, 2014
- Main results expected
- Sep 15, 2017
- Fully finished
- Dec 2026
- Results posted
- Dec 12, 2018
What counts as success
The trial's main goal(s), called the “primary outcome.”
Overall Survival (OS)
Measured over: From Randomization Date to Date of Death from Any Cause (Up to 32 Months)
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT02152631 · record last updated 2026-02-06 · checked 2026-11-09 15:42 UTC